Slide 1: Phase II - USAISR Platelet Results
Phase II - USAISR Platelet Results 22 May 2026 Vitrafy Life Sciences Limited (ASX: VFY) ACN 622 720 254 vitrafy.com Strictly Private & Confidential 1
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (the Company). Eligible recipients Statements in this presentation are made only as at the date of this presentation and the information This presentation is provided to you as an investo
Slide 3: Key Highlights
Key Highlights USAISR results confirm Vitrafy cryopreservation ecosystem outperforms regulatory and quality standards across all platelet protocols tested. Independent Category First 94% US Army Opportunity Validation Post thaw recovery - no-wash Largest blood platelet testing protocol, with high fu
Slide 4: Phase II In-Vitro Study Background & Aims
Phase II In-Vitro Study Background & Aims Study Aim CRADA Framework Independent Validation Assess and determine Conducted under the Conduct independent, U.S. Vitrafy’s cryopreservation Cooperative Research and Army-authored validation ecosystem capability to Development Agreement by the U.S. Army In
Slide 5: Results - Platelet Recovery vs Fresh
Results - Platelet Recovery vs Fresh All protocols tested using Vitrafy’s cryopreservation ecosystem exceeded the regulatory standard and quality guidelines. 3% DMSO no-wash protocol delivered the highest performance with a 94% post-thaw recovery Phase II Post-Thaw Platelet Recovery - % of Pre-Freez
Slide 6: Results - Platelet Functionality vs Fresh
Results - Platelet Functionality vs Fresh Key platelet functionality metrics were measured post thaw – including clot strength and the retention of key surface receptors. Functionality Markers — % of Pre-Freeze (Fresh) Baseline 100.0 94.4 83.8 81.9 78.9 80.0 73.0 59.6 60.0 45.8 40.0 26.6 20.5 20.0 0
Slide 7: Outlook
Outlook In Vitro validation milestone complete— multiple pathways now activated. Battlefield & forward operating FDA medical device registration (GUARDION) – H1 FY27 Phase II Results Publication (military & civilian) – H1 FY27 FDA, Military & Civilian blood network engagement 7